Suppr超能文献

家族性高胆固醇血症患者中,低密度脂蛋白受体基因型对普伐他汀与考来烯胺联合降低胆固醇的反应差异

Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.

作者信息

Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H

机构信息

Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

出版信息

Am J Cardiol. 1998 Jul 1;82(1):113-7. doi: 10.1016/s0002-9149(98)00230-6.

Abstract

We compared the effects of cholesterol-lowering therapy on 2 patient groups genetically defined as heterozygous for familial hypercholesterolemia (FH), 5 with a deletion of exon 15 (FH(Tonami-1)), and 7 with a point mutation at codon 664 (FH(Kanazawa-2)). There were significant differences in both serum and low-density lipoprotein cholesterol reductions between the 2 groups after combination therapy with pravastatin and cholestyramine, and the overall effect of genotype on serial changes in both was significant.

摘要

我们比较了降胆固醇疗法对两组经基因定义为家族性高胆固醇血症(FH)杂合子患者的影响,其中5例为第15外显子缺失(FH(Tonami - 1)),7例为密码子664处存在点突变(FH(Kanazawa - 2))。在普伐他汀和考来烯胺联合治疗后,两组患者的血清胆固醇和低密度脂蛋白胆固醇降低情况均存在显著差异,并且基因型对两者系列变化的总体影响显著。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验